

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	037003-0280727	2001-30-0080CP1

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Braslawsky, et al.

Appln. No.: 10/058,069

Filing Date: January 29, 2002

Examiner: TBA Group Art Unit: 1642

Date: October 29, 2003 Page 1 of 12

## U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
DB	AR	5,435,990	07/1995	Cheng, et al.	424	153	
	BR	5,512,443	04/1996	Schlom, et al.	435	7.23	
	CR	5,756,065	05/1998	Wilson, et al.	424	1.53	
	DR	5,877,291	03/1999	Mezes, et al.	530	387.3	
	ER	5,891,996	04/1999	Mateo de Acosta del Rio, et al.	530	387.3	
	FR	5,892,019	04/1999	Schlom, et al.	536	23.53	
	GR	5,892,020	04/1999	Mezes, et al.	536	23.53	
	HR	5,976,531	11/1999	Mezes, et al.	424	133.1	
	IR	5,993,813	11/1999	Mezes, et al.	424	133.1	
	JR	6,051,225	04/2000	Mezes, et al.	424	133.1	
	KR	6,103,889	08/2000	Whitlow, et al.	536	23.53	
	LR	6,121,022	09/2000	Presta, et al.	435	69.7	
DB	MR	6,165,745	12/2000	Ward, et al.	435	69.1	

## FOREIGN PATENT DOCUMENTS


		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
						Enclosed	No
DB	NR	0 365 997 B1	09/1994	EP	Mezes, et al.		
	OR	0 394 277 B1	01/1998	EP	Schlom, et al.		
	PR	0 327 378 B1	11/1996	EP	Morrison et al.		
	QR	WO 00/26394	05/2000	PCT	Kashmiri, et al.		
	RR	WO 89/01783	02/1989	PCT	Bodmer, et al.		
	SR	WO 97/11370	03/1997	PCT	Leung, et al.		
	TR	WO 99/43816	09/1999	PCT	Anderson, et al.		
	UR	WO 95 09917	04/1995	PCT	Univ. of CA		
	VR	WO 98 05787	02/1998	PCT	Squibb Bristol Myers Co.		
DB	WR	WO 99 36105	07/1999	PCT	MCA Dev BV; Vriesendorp Huibert M		

## OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

DB	XR	Goel et al., Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application, (2000), <i>Cancer Research</i> , 60:6964-6971.
DB	YR	Jiang et al., Enhanced effector functions of dimeric forms of IDEC -C2B8 (Rituximab), 1999, <i>Blood</i> , 94(10):86A (Abstract).
DB	ZR	Slavin-Chiorini et al., A CDR-grafted (humanized) domain-deleted antitumor antibody, (1997), <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 5(12):305-316.

*Harold Blumenthal*

*7/29/04*



DB	AAR	Slavin-Chiorini et al., Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins, (1995), <i>Cancer Research</i> , 55:5957-5967.
DB	BBR	Coloma et al., Design and production of novel tetravalent bispecific antibodies, (1997), <i>Nature Biotechnology</i> , 15(2):159-163.
DB	CCR	Ghetie et al., Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells, (1997), <i>PNAS of USA</i> , 94:7509-7514.
DB	DDR	International Search Report dated April 11, 2003, for PCT Application PCT/US02/02373

Examiner Paul Blahut Date Considered: 7/29/04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.